In the field of vaccine development, the delivery system is one of the key factors determining vaccine effectiveness. We focus on lipid nanoparticles (LNP) technology, providing comprehensive solutions for vaccine development, helping you overcome the limitations of traditional vaccine delivery systems, accelerate vaccine development, and improve vaccine stability and immunogenicity.
Low delivery efficiency: Traditional vaccine delivery systems face difficulties in efficiently transporting antigens to target cells which results in inadequate immune responses.
Poor stability: mRNA vaccines face degradation when stored at room temperature which necessitates cold chain transportation and storage conditions thereby escalating both costs and logistical complexity.
Difficulty in targeted delivery: Traditional delivery systems mostly reach the liver specifically but they fail to target other tissues or cells accurately.
Long development cycles: Developing vaccines requires several complicated procedures with traditional methods demanding significant time investment and manual effort.
Safety concerns: Certain vaccine delivery systems can provoke harmful immune responses which compromise safety.
Inability to activate mucosal immunity: Injection-based traditional vaccines fail to activate mucosal immunity in the respiratory tract which restricts their ability to protect against some infectious diseases.
Design and Synthesis: Our team develops and manufactures appropriate lipid nanoparticles that match your vaccine type requirements (e.g., mRNA vaccines, protein subunit vaccines) as well as specific targeting needs. Our comprehensive lipid library allows quick identification of optimal lipid mixtures that deliver antigens effectively and stimulate strong immune responses.
Composition Optimization: We modify lipid nanoparticle compositions by adjusting lipid ratios and structures to achieve desired physicochemical properties which improve particle size, surface charge and encapsulation efficiency to boost vaccine stability and immunogenicity.
Matching Antigens and Adjuvants: Our team pairs synthesized lipid nanoparticles with your vaccine antigens and adjuvants to refine the formulation ratio which improves vaccine immunogenicity. We examine different formulations to determine their impact on immune responses so that the vaccine can achieve optimal results.
Stability Enhancement: Our addition of stabilizers and improved storage conditions lengthens the shelf life of vaccines and cuts down both cold chain requirements and the financial and operational complexity of vaccine use.
Laboratory-Scale Preparation: Laboratory-scale lipid nanoparticles are produced using advanced microfluidic mixing technology which allows rapid and uniform mixing that results in consistent particle size and high encapsulation efficiency.
Pilot and Large-Scale Production: The laboratory preparation process expands into pilot and large-scale production operations while optimizing production methods to achieve better efficiency and consistent product quality which supports clinical trials and commercial manufacturing needs.
Comprehensive Testing: Our laboratory utilizes dynamic light scattering instruments, nanoparticle tracking analysis devices, and capillary electrophoresis systems to examine fundamental parameters including particle size and distribution, surface charge, encapsulation efficiency, and purity which are essential for meeting product quality standards.
Stability Testing: Long-term stability tests allow us to observe how lipid nanoparticles change in physicochemical properties across different storage conditions while evaluating vaccine shelf life to ensure quality before commercial release.
In Vitro Studies: Our cell-level experiments examine cellular uptake efficiency, intracellular transport, antigen expression and immune activation capabilities of lipid nanoparticle vaccines to generate data for later animal-based research.
Animal Studies: Our research team investigates vaccine immune responses across different animal models to measure immunogenicity, protective effectiveness, and safety which informs clinical trial strategies and development.
Our team engages with you to identify your vaccine development objectives and antigen types together with target tissues and specific requirements to develop a project plan through collaboration.
The project plan guides us through the design of lipid nanoparticle composition and structure while enabling small-scale synthesis followed by preliminary performance tests.
We combine synthesized LNPs with your vaccine antigens and adjuvants then optimize the formulation and production process before initiating pilot-scale production and performing extensive product quality testing.
We execute extensive quality control testing on the manufactured LNPs by examining particle size, encapsulation efficiency, and stability metrics while also performing long-term stability tests to guarantee consistent product performance throughout its shelf life.
Our team supports your preclinical research for LNP vaccines through in vitro and animal studies while delivering technical and data expertise for seamless progression to clinical trials.
Using high-throughput screening technology, we quickly evaluate how different lipid combinations and formulations affect LNP performance, speeding up the optimization process.
Using microfluidic mixing technology, we ensure rapid and uniform mixing of lipid and antigen solutions, producing lipid nanoparticles with consistent particle size and high encapsulation efficiency.
We use advanced equipment such as dynamic light scattering instruments and nanoparticle tracking analysis devices to comprehensively test and analyze key parameters such as particle size, size distribution, surface charge, and encapsulation efficiency, ensuring that product quality meets requirements.
Professional R&D TeamThe team possesses substantial experience in developing lipid nanoparticles and vaccines alongside strong technical skills and innovative proficiency.
Advanced Technology PlatformOur research and development team uses internationally leading analytical instruments like high-throughput screening systems and microfluidic mixing devices to offer robust technological support in LNP development and quality control.
Strict Quality Control SystemOur quality management system maintains strict control throughout the entire production process from raw material procurement to finished product release to deliver products with stable and reliable quality.
Efficient Project ManagementOur efficient project management processes enable us to maintain project timelines while delivering updates to you in a timely manner and adhering to specified time and budget constraints.
The category includes vaccines for influenza and COVID-19 as well as HPV vaccines. LNPs improve both the immune response and protective effectiveness of these vaccines.
Therapeutic vaccines that employ LNP technology target multiple cancer types by activating the immune system to attack tumor cells which introduces novel treatment options and hope for patients.
The encapsulation of gene editing tools or nucleic acid drugs in LNPs produces gene-level vaccine effects which create new treatment possibilities for genetic diseases and rare conditions.
LNP vaccines offer advantages such as higher delivery efficiency, better stability, and precise targeting. They effectively protect vaccine antigens from degradation by intracellular enzymes, improving antigen delivery efficiency and enhancing immune responses. Additionally, the composition and structure of LNPs can be flexibly adjusted to meet the needs of different vaccines, enabling targeted delivery to specific immune cells or tissues.
LNP vaccines have demonstrated good safety profiles in clinical applications. Components such as ionizable lipids and helper lipids can be metabolized and cleared from the body without long-term accumulation. Moreover, LNP vaccines do not contain live viruses or pathogens, reducing the safety risks associated with vaccines.
The development cycle for LNP vaccines varies depending on the complexity of the project and specific requirements. Generally, it takes about 6 months to 1 year from lipid nanoparticle design and synthesis to formulation optimization and process development, followed by small-scale production. If the project progresses smoothly with minimal need for large-scale formulation adjustments or process optimization, the development cycle may be shorter.
Yes, our LNP services can be customized based on the specific needs of the client. Whether it is for vaccine development targeting specific diseases or optimizing immune requirements for certain populations, we can provide personalized LNP solutions to meet your unique needs in vaccine development.
